Artificial Intelligence In Cancer Research – Precision Therapeutics
(NASDAQ Stock Trading Symbol: AIPT) formerly Skyline Medical executives were interviewed on the Money Info Investing News Show August 8, 2018.
See more at:
Precision Therapeutics is at the Forefront in Medical Advancement and Innovation. They are leaders in the field of using artificial intelligence for cancer research.
The Company arose as a Joint Venture Between Skyline Medical and Helomics. Precision Therapeutics Is Now Bringing Precision Medicine to the Diagnosis and Treatment of Cancer.
Harnessing the power of artificial intelligence, Precision Therapeutics is working with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for cancer patients, which is leading to much more effective treatments for the patients of today and tomorrow.
See more at the corporate website:
Precision Therapeutics (NASDAQ: AIPT) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, through its Skyline Medical division.
Skyline Medical Inc. has a fully automated, patented, and FDA cleared surgical fluid disposal device-the STREAMWAY System-that virtually eliminates operating room workers’ exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment.
Skyline Medical’s Automated ‘Streamway’ System Transformed How Laboratories Safely Dispose of Medical Fluid Waste. See more at:
Precision Therapeutics will hold a business update conference call on August 14, 2018.
See more at: http://investors.skylinemedical.com/news-releases/news-release-details/precision-therapeutics-hold-business-update-conference-call-0
Precision Therapeutics has also announced the formation of a subsidiary, TumorGenesis to pursue a new rapid approach to growing tumors in the laboratory, which essentially “fools” the cancer cells into thinking they are still growing inside the patient. Precision Therapeutics and Helomics have also announced a proposed joint venture with GLG Pharma focused on using their combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially those who present with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new partnerships and considering acquisitions in the precision medicine space.
Artificial Intelligence Cancer Research Stock – AIPT Stock News